Professional
Added to YB: 2025-08-29
Pitch date: 2025-08-27
VIR [bullish]
Vir Biotechnology, Inc.
+27.37%
current return
Author Info
No bio for this author
Company Info
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Market Cap
$783.3M
Pitch Price
$5.28
Price Target
14.00 (+109%)
Dividend
N/A
EV/EBITDA
-0.77
P/E
-1.55
EV/Sales
22.36
Sector
Biotechnology
Category
value
BofA Securities Upgrades $VIR to Buy, Raises PT to $14
VIR: BofA upgrades to Buy, $14 PT (from $12). Stock down 40% YTD on catalyst concerns & cash burn fears. Undervalued HDV liver treatment asset ($1B+ peak sales potential), pivotal ECLIPSE Phase 3 trials warrant spend with readouts late 2026. Masked T-cell engager oncology programs may differentiate vs competitors in large cancer markets.
Read full article (1 min)